摘要
[目的]探讨吉西他滨或卡培他滨联合放疗治疗局部晚期胰腺癌的疗效和安全性。[方法 ]34例不可手术切除的局部晚期胰腺癌患者,分为吉西他滨联合放疗组(A组,17例)和卡培他滨联合放疗组(B组,17例)。观察两组患者的有效率、不良反应及生存情况。[结果]A组与B组总有效率分别为70.6%vs 41.2%,1年生存率58.8%vs 35.3%,2年生存率29.4%vs 17.6%,1年局部控制率52.9%vs 35.3%,2年局控率23.5%vs 11.8%,均显示出A组有较好的生存和局部控制优势,但两组差异无统计学意义(P>0.05)。A组血液学不良反应发生率较B组高,而B组消化道不良反应发生率较A组高,多为Ⅰ/Ⅱ级,患者可耐受,两组不良反应差异无统计学意义(P>0.05)。[结论]吉西他滨联合外放疗治疗局部晚期胰腺癌有一定的疗效优势。
[Purpose] To investigate the efficacy and safety of gemcitabine or capecitabine combination with radiotherapy in the treatment of locally advanced pancreatic cancer. [Methods] Thirty-four cases with locally advanced unresectable pancreatic cancer were divided into gemcitabine combined with radiotherapy group（group A,17 cases）and capecitabine combined with radiotherapy group（group B,17 cases）. Response rate,toxicities and survival of the two groups were analyzed. [Results] The response rate of group A and group B was 70.6% vs 41.2%;1-year survival rate,58.8% vs 35.3%;2-year survival rate,29.4% vs 17.6%;1-year local control rate,52.9% vs35.3%;2- year local control rate,23.5% vs 11.8%. Group A had superior survival and local control advantages compared with group B,but no significant difference was found between the two groups（P〉0.05）. The incidence of hematologic toxicities in group A was higher than that in group B,while gastrointestinal toxicities in group B was higher than that in group A. And these toxicities in the two groups were mostly grade Ⅰ/Ⅱ and tolerable,and no significant difference was found（P〉0.05）. [Conclusion] Gemcitabine combined with radiotherapy seems to have certain efficacy advantage in the treatment of locally advanced pancreatic cancer patients.
出处
《肿瘤学杂志》
CAS
2015年第7期591-595,共5页
Journal of Chinese Oncology
关键词
胰腺肿瘤
同步放化疗
吉西他滨
卡培他滨
pancreatic neoplasms
concurrent chemoradiotherapy
gemcitabine
capecitabine
